Ophthalmology Therapeutics: Does current pipeline innovation hold the potential to affect the future ophthalmology market?

This Frontier Pharma: Ophthalmology Therapeutics assesses first-in-class innovation in the ophthalmology pipeline, highlighting key trends in the distribution of these products.

Pune, India - March 14, 2018 /MarketersMedia/ —

The pipeline is varied in terms of molecular targets and molecule types. Products acting on the immune system and neurotransmitter signaling are the most prevalent, but no single target dominates by any clear margin. There are a total of 194 first-in class pipeline products in development for ophthalmologic indications 38% of the 512 pipeline products for which there is a disclosed molecular target. Encompassing gene therapies, slowing of the visual cycle and antisense therapies, the pipeline appears robust and has huge potential to strengthen treatment options for ophthalmological disorders.

Access Report Details at: https://www.themarketreports.com/report/frontier-pharma-ophthalmology-therapeutics-gene-therapies-and-first-in-class-targets-offer-novel-treatments-for-substantial-unmet-needs-in-a-pipeline-dominated-by-angiogenic-and-immune-signaling-drugs

Reasons To Buy
• Understand the current clinical and commercial landscape. This includes a comprehensive study of disease pathogenesis, diagnosis and prognosis, and the treatment options available.
• Visualize the composition of the ophthalmological disorders market in terms of dominant molecule types and targets, and understand the current unmet needs and how they can be addressed. This knowledge allows a competitive understanding of gaps in the market.
• Analyze the ophthalmological disorders pipeline and stratify by stage of development, molecule type and molecular target. There are strong signs in the pipeline that the industry is seeking novel approaches to treating ophthalmological disorders to overcome the overwhelming level of unmet need.
• Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix, first-in-class products have been assessed and ranked according to clinical potential. Promising early-stage targets have been reviewed in greater detail.
• Identify commercial opportunities in the ophthalmological disorders deals landscape by analyzing trends in licensing and co-development deals, and a curated list of ophthalmological disorder therapies that have not yet been involved in deals, and may offer potential investment opportunities.

Get this report at: https://www.themarketreports.com/report/buy-now/935550

In the past the ophthalmological disorders therapy area has suffered from a lack of full understanding of the pathophysiology and underlying mechanisms of the diseases. However, as this knowledge has improved vastly in recent years, potential targets have been identified for treatment. As well as the main disorders previously mentioned, there is also interest in developing treatments for indications such as allergic conjunctivitis and retinitis pigmentosa. The approval of a gene therapy for retinitis pigmentosa is indicative of this progress, and represents the first gene therapy approved for an inherited condition by the FDA.

Inquire for more details at: https://www.themarketreports.com/report/ask-your-query/935550

Contact Info:
Name: Shirish Gupta
Email: sales@themarketreports.com
Organization: The Market Reports
Address: SF-29, Sacred World, Wanawadi
Phone: 16314071315

Source URL: https://marketersmedia.com/ophthalmology-therapeutics-does-current-pipeline-innovation-hold-the-potential-to-affect-the-future-ophthalmology-market/314326

For more information, please visit https://www.themarketreports.com/report/frontier-pharma-ophthalmology-therapeutics-gene-therapies-and-first-in-class-targets-offer-novel-treatments-for-substantial-unmet-needs-in-a-pipeline-dominated-by-angiogenic-and-immune-signaling-drugs%20%20

Source: MarketersMedia

Release ID: 314326

More Press Releases

Global shares rise as traders shrug off new China-US tariffs

Sep 19, 2018

TOKYO — Global shares were mostly higher Wednesday despite jitters over the escalating trade dispute between the U.S. and China. KEEPING SCORE: France's CAC 40 edged up 0.3 percent to 5,380.16, while Germany's DAX gained 0.2 percent to 12,185.36. Britain's FTSE 100 was flat at 7,301.46. U.S. shares were set to rise with Dow futures up 0.1 percent at 26,325. S&P 500 futures were flat at 2,911.80. ASIA'S DAY: Japan's benchmark Nikkei 225 added 1.1 percent to finish at 23,672.52. Australia's S&P/ASX 200 was up 0.5 percent at 6,190.00. South Korea's Kospi was virtually unchanged at 2,308.46. Hong Kong's Hang...

Asian shares rise as traders shrug off new China-US tariffs

Sep 19, 2018

TOKYO — Asian shares were mostly higher Wednesday, despite jitters over the escalating trade dispute between the U.S. and China. KEEPING SCORE: Japan's benchmark Nikkei 225 added 1.4 percent in early trading to 23,741.29. Australia's S&P/ASX 200 rose 0.4 percent to 6,195.70. South Korea's Kospi slipped 0.3 percent to 2,303.34. Hong Kong's Hang Seng advanced 1.0 percent to 27,355.73, while the Shanghai Composite also jumped 1.0 percent, to 2,726.27. TRADE TENSIONS: The administration of President Donald Trump has decided to impose tariffs on an additional $200 billion of Chinese goods. China responded by saying it will go ahead with plans...

The Latest: China's premier appeals for global support

Sep 19, 2018

NEW YORK — The Latest on the U.S.-China trade war (all times local): ___ 11:30 p.m. China's No. 2 leader has appealed for global support for free trade following tit-for-tat U.S. and Chinese tariff hikes in an escalating battle over Beijing's technology policy. Premier Li Keqiang said Wednesday in a speech to a business conference that disputes must be worked out through consultation. China announced a tariff hike on $60 billion of American imports on Tuesday in response to U.S. President Donald Trump's increase on $200 billion of Chinese goods. Speaking at the World Economic Forum in the eastern city...

Venezuela doubles down on Chinese money to reverse crisis

Sep 19, 2018

CARACAS, Venezuela — Venezuelan President Nicolas Maduro said Tuesday that new investments from China will help his country dramatically boost its oil production, doubling down on financing from the Asian nation to turn around its crashing economy. Already a major economic partner, China has agreed to invest $5 billion more in Venezuela, Maduro said following a recent trip to Beijing, adding that the money would help it nearly double its oil exports to China. "We are taking the first steps into a new economic era," he said. "We are on track to have a new economy, and the agreements with...

Markets Right Now: Markets shrug off trade and end higher

Sep 19, 2018

NEW YORK — The latest on developments in financial markets (all times local): 4 p.m. Investors shrugged off the latest escalation of trade tensions between the U.S. and China and sent stocks broadly higher on Wall Street. Major U.S. indexes on Tuesday gained back nearly all the ground they lost the day before. Technology and consumer-focused companies had some of the biggest gains. Chipmaker Micron Technology rose 4.1 percent and Netflix jumped 5 percent. Ferrari rose 4.2 percent after the sportscar maker announced a new lineup of models. The S&P 500 index rose 15 points, or 0.5 percent, to 2,904....

Subscribe to our newsletter!

Your Name

Your Email Address